TY - JOUR
T1 - Diet, gut microbiome and their end-metabolites associate with acute pancreatitis risk
AU - Yazici, Cemal
AU - Thaker, Sarang
AU - Castellanos, Karla K.
AU - Al Rashdan, Haya
AU - Huang, Yongchao
AU - Sarraf, Paya
AU - Boulay, Brian
AU - Grippo, Paul
AU - Gaskins, H. Rex
AU - Danielson, Kirstie K.
AU - Papachristou, Georgios I.
AU - Tussing-Humphreys, Lisa
AU - Dai, Yang
AU - Mutlu, Ece R.
AU - Layden, Brian T.
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Introduction Diet and decreased gut microbiome diversity has been associated with acute pancreatitis (AP) risk. However, differences in dietary intake, gut microbiome and their impact on microbial end-metabolites have not been studied in AP. We aimed to determine differences in i) dietary intake ii) gut microbiome diversity and sulfidogenic bacterial abundance, and iii) serum short-chain fatty acid (SCFA) and hydrogen sulfide (H2S) concentrations in AP and control subjects. Methods This case-control study recruited 54 AP and 46 control subjects during hospitalization. Clinical and diet data, stool and blood samples were collected. 16S rDNA sequencing was used to determine gut microbiome alpha diversity and composition. Serum SCFA and H2S levels were measured. Machine learning (ML) model was used to identify microbial targets associated with AP. Results AP patients had decreased intake of vitamin D3, whole grains, fish, and beneficial eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids. AP patients also had lower gut microbiome diversity (p=0.021) and higher abundance of sulfidogenic bacteria including Veillonella and Haemophilus which were associated with AP risk. Serum acetate and H2S concentrations were significantly higher in the AP group (p < 0.001 and p=0.043, respectively). ML model had 96% predictive ability to distinguish AP patients from controls. Conclusions AP patients have decreased beneficial nutrient intake and gut microbiome diversity. Increased abundance of H2S producing genera in the AP, SCFA producing genera in the control group, and predictive ability of ML model to distinguish AP patients indicates that diet, gut microbiota and their end-metabolites play a key role in AP.
AB - Introduction Diet and decreased gut microbiome diversity has been associated with acute pancreatitis (AP) risk. However, differences in dietary intake, gut microbiome and their impact on microbial end-metabolites have not been studied in AP. We aimed to determine differences in i) dietary intake ii) gut microbiome diversity and sulfidogenic bacterial abundance, and iii) serum short-chain fatty acid (SCFA) and hydrogen sulfide (H2S) concentrations in AP and control subjects. Methods This case-control study recruited 54 AP and 46 control subjects during hospitalization. Clinical and diet data, stool and blood samples were collected. 16S rDNA sequencing was used to determine gut microbiome alpha diversity and composition. Serum SCFA and H2S levels were measured. Machine learning (ML) model was used to identify microbial targets associated with AP. Results AP patients had decreased intake of vitamin D3, whole grains, fish, and beneficial eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids. AP patients also had lower gut microbiome diversity (p=0.021) and higher abundance of sulfidogenic bacteria including Veillonella and Haemophilus which were associated with AP risk. Serum acetate and H2S concentrations were significantly higher in the AP group (p < 0.001 and p=0.043, respectively). ML model had 96% predictive ability to distinguish AP patients from controls. Conclusions AP patients have decreased beneficial nutrient intake and gut microbiome diversity. Increased abundance of H2S producing genera in the AP, SCFA producing genera in the control group, and predictive ability of ML model to distinguish AP patients indicates that diet, gut microbiota and their end-metabolites play a key role in AP.
KW - Acute pancreatitis
KW - diet
KW - hydrogen sulfide
KW - microbiota
UR - http://www.scopus.com/inward/record.url?scp=85160565031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160565031&partnerID=8YFLogxK
U2 - 10.14309/ctg.0000000000000597
DO - 10.14309/ctg.0000000000000597
M3 - Article
C2 - 37162146
AN - SCOPUS:85160565031
SN - 2155-384X
JO - Clinical and Translational Gastroenterology
JF - Clinical and Translational Gastroenterology
ER -